Literature DB >> 2437547

Intrathecal cholecystokinin interacts with morphine but not substance P in modulating the nociceptive flexion reflex in the rat.

Z Wiesenfeld-Hallin, R Duranti.   

Abstract

The effect of intrathecal (IT) cholecystokinin (CCK), substance P (SP) and morphine (MO) on spinal cord excitability was studied in decerebrate, spinalized rats. CCK had a weaker facilitatory effect on the nociceptive flexion reflex than SP. The possible functional significance of the coexistence of CCK and SP in neurons projecting to the spinal cord was tested by coadministration of the two peptides. At the doses tested no synergistic interaction on the reflex was found with CCK and SP. IT MO caused a brief enhancement followed by a prolonged depression of the reflex. A high dose of CCK injected prior to MO increased the facilitatory effect and decreased the depressive effect of the opiate on the reflex. The effect of desulfated (D) CCK was similar to CCK but at a higher dose. Naloxone (NAL) had a similar effect as CCK when administered prior to MO. The MO-induced depression of the reflex was readily reversed by NAL, but not by CCK. The results indicate that CCK may prevent the inhibitory effect of MO on spinal cord excitability to nociceptive stimulation, but does not reverse it. CCK may alter the balance of excitation-inhibition between various types of dorsal horn interneurons that are involved in the transmission of nociceptive information.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437547     DOI: 10.1016/0196-9781(87)90179-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

2.  PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.

Authors:  Z Wiesenfeld-Hallin; X J Xu; J Hughes; D C Horwell; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.

Authors:  X J Xu; Z Wiesenfeld-Hallin; J Hughes; D C Horwell; T Hökfelt
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

4.  Oral opioid administration and hyperalgesia in patients with cancer or chronic nonmalignant pain.

Authors:  Igor Reznikov; Dorit Pud; Elon Eisenberg
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

5.  Delta-opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones.

Authors:  A F Sullivan; A H Dickenson; B P Roques
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

6.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.